A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

被引：0

作者：

Tara L. Lin

Laura F. Newell

Robert K. Stuart

Laura C. Michaelis

Eric Rubenstein

Helen S. Pentikis

Timothy Callahan

Donna Alvarez

Barry D. Liboiron

Lawrence D. Mayer

Qi Wang

Kamalika Banerjee

Arthur C. Louie

机构：

[1] University of Kansas Medical Center,Hollings Cancer Center

[2] Knight Cancer Institute,undefined

[3] Oregon Health and Science University,undefined

[4] Medical University of South Carolina,undefined

[5] Medical College of Wisconsin,undefined

[6] Oncology and Hematology Specialists,undefined

[7] Franciscan Health,undefined

[8] SAJE Consulting,undefined

[9] Biomedical Systems,undefined

[10] Celator/Jazz Pharmaceuticals,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2019年 / 84卷

关键词：

Acute myeloid leukemia; Acute lymphoblastic leukemia; Cardiac repolarization; Pharmacokinetics; Pharmacodynamics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：163 / 173

页数：10

共 50 条

[21] V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
Agresta, Laura
O'Brien, Maureen M.
Mizuno, Kana
Norris, Robin
Breese, Erin H.
Phillips, Christine L.
Burns, Karen
Mizukawa, Benjamin
Lee, Lynn
Lane, Adam
Lorsbach, Robert B.
Ryan, Thomas D.
Desai, Pankaj B.
Vinks, Alexander A.
Grimes, H. Leighton
Perentesis, John P.
Absalon, Michael J.
BLOOD, 2019, 134
[22] Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias
Feldman, Eric J.
Lancet, Jeffrey
Kolitz, Jonathan E.
Ritchie, Ellen
List, Alan F.
Asatiani, Ekatherine
Curcio, Tania J.
Burton, Michelle
Fricano, Marge
Swenson, Christine
Mayer, Lawrence D.
Louie, Arthur C.
BLOOD, 2008, 112 (11) : 1025 - 1025
[23] Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors
Nianhang Chen
Sant P. Chawla
Elena Gabriela Chiorean
William L. Read
Mayer Gorbaty
Alain C. Mita
Lotus Yung
Peter Bryan
Richard McNally
Markus F. Renschler
Sunil Sharma
Cancer Chemotherapy and Pharmacology, 2013, 71 : 1083 - 1094
[24] Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
Munisamy, Sreetharan
Choudhuri, Satarupa
BLOOD, 2021, 138
[25] Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors
Chen, Nianhang
Chawla, Sant P.
Chiorean, Elena Gabriela
Read, William L.
Gorbaty, Mayer
Mita, Alain C.
Yung, Lotus
Bryan, Peter
McNally, Richard
Renschler, Markus F.
Sharma, Sunil
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1083 - 1094
[26] A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure
Nazha, Aziz
Mukherjee, Sudipto
Advani, Anjali S.
Waldron, Madeline
Siebenaller, Caitlin
Thomas, Jenna
Parsons, Eric
Carraway, Hetty E.
Gerds, Aaron T.
Patel, Bhumika J.
Sekeres, Mikkael A.
BLOOD, 2020, 136
[27] CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
Peterlin, Pierre
Le Bris, Yannick
Turlure, Pascal
Chevallier, Patrice
Menard, Audrey
Gourin, Marie-Pierre
Dumas, Pierre-Yves
Thepot, Sylvain
Berceanu, Ana
Park, Sophie
Hospital, Marie -Anne
Cluzeau, Thomas
Bouzy, Simon
Torregrosa-Diaz, Jose-Miguel
Drevon, Louis
Sapena, Rosa
Chermat, Fatiha
Ades, Lionel
Dimicoli-Salazar, Sophie
Chevret, Sylvie
Bene, Marie-Christine
Fenaux, Pierre
LANCET HAEMATOLOGY, 2023, 10 (07): : E521 - E529
[28] Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality
Borthakur, Gautam
Kantarjian, Hagop M.
DiNardo, Courtney D.
Daver, Naval
Jabbour, Elias J.
Kadia, Tapan
Garcia-Manero, Guillermo
Ravandi, Farhad
Pemmaraju, Naveen
Konopleva, Marina
Ohanian, Maro
Wierda, William G.
Jain, Nitin
Xiao, Lian-Chun
Mukherjee, Paromita
Brandt, Mark
Cortes, Jorge E.
BLOOD, 2017, 130
[29] Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience
Fianchi, Luana
Guolo, Fabio
Marchesi, Francesco
Cattaneo, Chiara
Gottardi, Michele
Restuccia, Francesco
Candoni, Anna
La Barbera, Elettra Ortu
Fazzi, Rita
Pasciolla, Crescenza
Finizio, Olimpia
Fracchiolla, Nicola
Delia, Mario
Lessi, Federica
Dargenio, Michelina
Bonuomo, Valentina
Del Principe, Maria Ilaria
Zappasodi, Patrizia
Picardi, Marco
Basilico, Claudia
Piedimonte, Monica
Minetto, Paola
Giordano, Antonio
Chiusolo, Patrizia
Prezioso, Lucia
Buquicchio, Caterina
Melillo, Lorella Maria Antonia
Zama, Daniele
Farina, Francesca
Mancini, Valentina
Terrenato, Irene
Rondoni, Michela
Urbino, Irene
Tumbarello, Mario
Busca, Alessandro
Pagano, Livio
CANCERS, 2023, 15 (13)
[30] Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351
Makishima, Hideki
Mikasa, Taisuke
Isogaya, Kento
Miyamoto, Toshihiro
Yamauchi, Takuji
Yokota, Akira
Onozawa, Masahiro
Ando, Kiyoshi
Ogawa, Yoshiaki
Usuki, Kensuke
Yamauchi, Takahiro
Ota, Shuichi
Takada, Satoru
Morita, Yasuyoshi
Ishikawa, Takayuki
Takenaka, Katsuto
Kuroda, Junya
Sekiguchi, Naohiro
Kawakita, Toshiro
Miyazaki, Yasushi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,

← 1 2 3 4 5 →